The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 3, 2023
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
April 3, 2023 (Issue: 1673)
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.